Grafa News and Videos — Page 141

Verastem Oncology (NASDAQ:VSTM) reported updated Phase 1/2 TARGET-D 101 trial results for VS-7375, an investigational oral KRAS G12D inhibitor, across multiple KRAS G12D-mutated solid tumors.

Yiren Digital (NYSE:YRD) reaffirmed its intention to continue implementing its previously announced share repurchase program of up to US$20 million.

High Templar Tech (NYSE:HTT) reported first-half 2026 shareholder net income of RMB416.9 million, compared with RMB461.9 million in the same period last year.

Oil prices moved higher after vessels were struck in the Strait of Hormuz and Iranian officials said new tactics were being used to target ships in the region.

Rhythm Pharmaceuticals (NASDAQ:RYTM) commercially launched IMCIVREE (setmelanotide) in Japan for patients with acquired hypothalamic obesity following its inclusion on the national insurance price list.

Alvotech (NASDAQ:ALVO) and Advanz Pharma submitted a regulatory application in Europe for AVT29, a proposed biosimilar referencing Eylea 8 mg, a treatment used for retinal diseases.

ASML (NASDAQ:ASML) reported third-quarter 2026 results with net sales of €11.7 billion, compared with higher profitability in the previous quarter due to improved gross margin and net income.

Danaher (NYSE:DHR) announced a collaboration with NVIDIA (NASDAQ:NVDA) to combine its scientific instruments and laboratory processes with artificial intelligence technologies.

Liberty Global (NASDAQ:LBTYA) received EU Commission approval for the sale of VodafoneZiggo’s passive tower assets to infrastructure investors for €669 million.

NVIDIA (NASDAQ:NVDA) committed $250 million in computing access to support U.K. researchers studying the safety and security of artificial intelligence agents.